FDA Approves Imdelltra (tarlatamab-dlle) for Extensive Stage Small Cell Lung Cancer
On May 16, 2024, the U.S. Food and Drug Administration (FDA) granted Imdelltra (tarlatamab-dlle) accelerated approval for people with extensive stage small cell lung cancer (ES-SCLC) following progression on or after platinum-based chemotherapy. The approval is based on results [...]